Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
Saskova, K.G., Kozisek, M., Rezacova, P., Brynda, J., Yashina, T., Kagan, R.M., Konvalinka, J.(2009) J Virol 83: 8810-8818
- PubMed: 19535439 
- DOI: 10.1128/JVI.00451-09
- Primary Citation of Related Structures:  
3GGU, 3U7S - PubMed Abstract: 
Darunavir is the most recently approved human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) and is active against many HIV type 1 PR variants resistant to earlier-generation PIs. Darunavir shows a high genetic barrier to resistance development, and virus strains with lower sensitivity to darunavir have a higher number of PI resistance-associated mutations than viruses resistant to other PIs ...